Pharmacogenomics for Neurohormonal Intervention in Heart Failure

Cardiology Clinics

Volumn 26, Issue 1, 2008, Pages 127-135

  McNamara, Dennis M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ARGININE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; ISOLEUCINE; ISOPRENALINE; NEUROHORMONE; NORADRENALIN; SERINE; THREONINE;

ALLELE; AMINO ACID SUBSTITUTION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; FUNCTIONAL GENOMICS; GENE DELETION; GENE INSERTION; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART FAILURE; HEART MUSCLE INJURY; HUMAN; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SYMPATHETIC TONE; TREATMENT PLANNING;

HEART FAILURE; HUMANS; NEUROTRANSMITTER AGENTS; PHARMACOGENETICS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 39649123987     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.12.002     Document Type: Review

References (54)

1. Darwin C. Natural selection. On the origin of species (1859), J. Murray, London 80
2. Osler W. Diseases of the circulatory system. The principles and practice of medicine (1892), D. Appleton and Co., New York 623-640
3. Ligget S.B. Pharmacogenetic applications of the human genome project. Nat Med 7 (2001) 281-283
4. Rigat B., Hubert C., Alhenc-Gelas F., et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86 (1990) 1343-1346
5. Rigat B., Hubert C., Corvol P., et al. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 20 (1992) 1433
6. Tiret L., Rigat B., Visvikis S., et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51 (1992) 197-205
7. Danser A.H., Derkx F.H., Hense H.W., et al. Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels. J Hypertens 16 (1998) 1879-1883
8. Cambien F., Poirier O., Lecerf L., et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359 (1992) 641-644
9. Ihnken R., Verho K., Gross M., et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med 125 1 (1996) 19-25
10. Andersson B., and Sylven C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 28 (1996) 162-167
11. Palmer B.R., Pilbrow A.P., Yandle T.G., et al. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol 41 (2003) 729-736
12. McNamara D.M., Holubkov R., Janosko K., et al. Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103 (2001) 1644-1648
13. McNamara D.M., Holubkov R., Postava L., et al. Phamacogenetic interactions between ACE inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Amer Coll Cardiol 44 (2004) 2019-2026
14. Campbell D., Aggrarwal A., Esler M., et al. Beta blockers, angiotenisn II, and ACE inhibitors in patients with heart failure. Lancet 358 (2001) 1609-1610
15. de Groote P., Helbecque N., Lamblin N., et al. Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. Eur J Heart Fail 6 (2004) 17-21
16. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100 (1999) 2312-2318
17. O'Toole L., Stewart M., Padfield P., et al. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on the response to angiotensin-converting inhibitors in patients with heart failure. J Cardiovasc Pharmacol 32 (1998) 988-994
18. Kurland L., Melhus H., Karlsson J., et al. Angiotensin-converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 19 (2001) 1783-1787
19. Cicoira M., Zanolla L., Rossi A., et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure associated with the ACE DD genotype. J Am Coll Cardiol 37 (2001) 1808-1812
20. Ciocoira M., Rossi A., Bonapace S., et al. Effects of ACE gene insertion/deletion polymorphism on response to sprironolactone in patients with chronic heart failure. Am J Med 116 (2004) 657-661
21. McNamara D.M., MacGowan G.A., and London B. Clinical importance of beta adrenoceptor polymorphisms in cardiovascular disease. Am J Pharmacogenomics 2 (2002) 73-78
22. Bristow M.R. Beta adrenergic receptor blockade in the failing heart. Circulation 101 (2000) 558-569
23. Buscher R., Herrmann V., and Insel P.A. Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Trends Pharmacol Sci 20 (1999) 94-99
24. Steinberg S.F. The molecular basis for distinct beta adrenergic receptor subtype action in cardiomyocytes. Circ Res 85 (1999) 1101-1111
25. Lefkowitz R.F., Rockman H.A., and Koch W.J. Catecholamines, cardiac beta adrenergic receptors and heart failure. Circulation 101 (2000) 1634-1637
26. Liggett S.B. Pharmacogenetics of relevant targets in asthma. Clin Exp Allergy 28 (1998) 77-79
27. 2 adrenergic receptor pharmacogenetics. Am J Respir Crit Care Med 161 (2000) S197-S201
28. Green S.A., Cole G., Jacinto M., et al. A polymorphism of the beta 2-adrenergic receptor within the fourth membrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268 (1993) 23116-23121
29. Turki J., Lorenz J.N., Green S.A., et al. Myocardial signaling defects and impaired cardiac function of human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA 93 (1996) 10483-10488
30. 2 adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102 (1998) 1534-1539
31. 2 adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 86 (2000) 834-840
32. 2 adrenoceptors. Circulation 103 (2001) 1048-1050
33. Feldman R.D. Adrenergic receptor polymorphisms in cardiac function (and dysfunction): a failure to communicate?. Circulation 1003 (2001) 1042-1043
34. 2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: the Bergen blood pressure study. Kidney Int 53 (1998) 1455-1460
35. 2 adrenergic receptor gene variations, blood pressure, and heart size in normal twins. Hypertension 35 (2000) 555-562
36. 1 adrenoceptor: identification and rapid screening assay. Lancet 353 (1999) 897-899
37. Levin M.C., Marullo S., Muntaner O., et al. The myocardium protective variant of the Gly-49 variant of the beta 1 adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 34 (2002) 30429-30435
38. Rathz D.A., Brown K.M., Kramer L.A., et al. Amino acid 49 polymorphisms of the human beta 1 adrenergic receptor affect agonist promoted trafficking. J Cardiovasc Pharmacol 39 (2002) 155-260
39. 1 adrenergic receptor. J Biol Chem 274 (1999) 12670-12674
40. Ranade K., Jorgenson E., Sheu W.H., et al. A polymorphism in the beta 1 receptor is associated with resting heart rate. Am J Hum Genet 70 (2002) 935-942
41. 1 adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 21 (2000) 1810-1812
42. Postava L., Mahlab D., Holubkov R., et al. β1 and β2 Adrenergic receptor polymorphisms and heart failure survival: interaction with beta blockade. [abstract]. Circulation 19 Suppl (2002) II-611
43. Liggett S.B., Wagoner L.E., Levin A.M., et al. Synergistic polymorphisms of beta 1 and alpha 2c adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347 (2002) 1135-1142
44. Liggett S.B. Late Breaking Clinical Trials. Presented at the Heart Failure Society of America. Toronto, September, 2004.
45. White H.L., de Boar R.A., Maqbool A., et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5 (2003) 463-468
46. Johnson J.A., Zineh I., Puckett B.J., et al. Beta-1 adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 74 (2003) 44-52
47. Brodde O.R., and Stein CM. The Gly389Arg beta 1 adrenergic receptor polymorphism: a predictor of response to beta-blocker treatment?. Clin Pharmacol Ther 74 (2003) 299-302
48. Kelly R.A., Balligand J.L., and Smith T.W. Nitric oxide and cardiac function. Circ Res 79 (1996) 363-380
49. Drexler H. Nitric oxide synthases in the failing human heart: a double-edged sword?. Circulation 99 (1999) 2972-2975
50. Philip I., Plantefeve G., Vuillaumier-Barrot S., et al. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. Circulation 99 (1999) 3096-3098
51. Tesauro M., Thompson W.C., Rogliani P., et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 97 (2000) 2832-2835
52. 298 variant of endothelial nitric oxide synthase: effect on survival for patients with congestive heart failure. Circulation 107 (2003) 1598-1602
53. Yang X.P., Liu Y.H., Sheseley E.G., et al. Endothelial nitric oxide gene knockout mice cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension 34 (1999) 24-30
54. Bedi M., Murali S., MacGowan G., et al. High dose ACE inhibitors reduces the impact of the NOS3 Asp298 variant on heart failure survival. Circulation 1085 (2003) IV-444